Everything below concerns amino acid substitution. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
=== Distributor's losses and impact === Though Darbar became the highest-grossing Tamil film of 2020, grossing ₹202–250, several distributors claimed that they incurred significant financial losses due to the film’s high acquisition costs and pre-release rights pricing. Trade analysts estimated that distributors collectively suffered losses of around ₹70 crore. It did not perform well in other Indian states, including Andhra Pradesh and Telangana, due to competition from Ala Vaikunthapurramuloo and Sarileru Neekevvaru, and the Hindi version was unsuccessful at the box office due to a lack of promotion. Following unsuccessful discussions with Lyca Productions, a group of distributors attempted to approach Rajinikanth seeking financial relief. Media reports stated that some distributors threatened protests, including hunger strikes, if their concerns were not addressed. Industry commentators later compared the situation to earlier Rajinikanth films such as Baba (2002), Kuselan (2008) and Lingaa (2014). Trade publications attributed the dispute primarily to the film’s high production and acquisition costs. Reports indicated that Rajinikanth and director A. R. Murugadoss received substantial remuneration, contributing to an increased production budget, while the film’s distribution rights were sold at premium rates. Some commentators cited the episode as part of a broader industry debate on the financial risks associated with high-budget star-driven films.
== Scope == EARS-Net tracks resistance rates reported in routine clinical antimicrobial susceptibility data from local and clinical laboratories, gathered by national surveillance programs and laboratory networks. Resistance status is determined according to EUCAST guidelines. Only data from invasive isolates (blood and cerebrospinal fluid) are included in EARS-Net. The antibiotics for which resistance is tracked varies by species, and is based on EUCAST recommendations. Resistance data is collected for these eight pathogens only:
=== Isomerisation === The chiral centers of a polypeptide chain can undergo racemization. Although it does not change the sequence, it does affect the chemical properties of the sequence. In particular, the L-amino acids normally found in proteins can spontaneously isomerize at the
=== Glycoprotein Ib-IX-V complex (GPIb-IX-V) === This transmembrane glycoprotein complex is composed of four subunits: GPIbα, GPIbβ, GPV and GPIX. Each of them has a variable number of leucine-rich repeats. GPIbα and GPIbβ are linked by disulfide bridges, while the GPV and GPIX associate non-covalently with the complex. The GPIbα subunit bears the binding site for von Willebrand factor (vWF), α-thrombin, leukocyte integrin αMβ2 and P-selectin. The binding between GPIbα and vWF mediates the capture of platelets to the injured vascular wall. The deficiency in glycoprotein Ib-IX-V complex synthesis leads to Bernard–Soulier syndrome.
== Use as a biomarker == Although a number of surrogate biomarkers exist for measuring the metabolic products of bone resorption, the serum CTX marker was chosen because it is both highly correlated to bone turnover rate and already available for detection in a laboratory test carried out by a major lab testing corporation. The CTX test measures for the presence and concentration of a crosslink peptide sequence of type I collagen, found, among other tissues, in bone. This specific peptide sequence relates to bone turnover because it is the portion that is cleaved by osteoclasts during bone resorption, and its serum levels are therefore proportional to osteoclastic activity at the time the blood sample is drawn. Serum levels in healthy patients not taking bisphosphonates tends to hover above 300 pg/mL.
Sources: en.wikipedia.org
=== Compounds in other oxidation states === Less frequently, indium forms compounds in oxidation state +2 and even fractional oxidation states. Usually such materials feature In–In bonding, most notably in the halides In2X4 and [In2X6]2−, and various subchalcogenides such as In4Se3. Several other compounds are known to combine indium(I) and indium(III), such as InI6(InIIICl6)Cl3, InI5(InIIIBr4)2(InIIIBr6), and InIInIIIBr4.
=== Mechanism of liver injury === The cause of the mild, transient serum enzyme elevations during imipenem-cilastatin therapy is not known. The cholestatic hepatitis attributed to imipenem-cilastatin and the carbapenems is probably immunoallergic and resembles the rare, clinically apparent liver injury that has been linked to penicillins and cephalosporins.
In 1942, the Nationalists conducted a major fiscal reorganization by abolishing provincial budgets and centralizing financial control, a move that ironically led to many local administrations relying even less on the central government because they had lost funding. These local administrations were forced to turn to other measures to support themselves. Liu Wenhui, who had already been involved in the opium trade prior to 1942, now faced the loss of his stipend from both the central government and the Sichuanese provincial government. Liu's budgetary situation had already been precarious: in 1939, Xikang's expenditures were around 5.4 million yuan, but non-opium income only amounted to 1.4 million yuan. Liu began growing opium on a systematic scale around the early 1940s. He instituted taxes on opium, taxes for not growing opium (the "laziness tax"), taxes on the import, export, and sale of opium, and "red light" taxes on opium dens. After 1942, each county in Xikang was assigned an annual tax quota of at least 100 dan (160,000 liang), with total revenues estimated at at least 3-4,000 dan. The price per liang of opium was one to two silver dollars in Xikang and three to four dollars in the Sichuan basin, not counting shortages. During the communist era, when opium consumption was strictly prohibited, Liu admitted that his strategy was one of "drinking poison to quench thirst." However, he blamed Chiang Kai-shek for forcing him into a situation where he had no other choice but to cultivate, trade, and tax opium.
=== Investigators === Investigators are often compensated for their work in clinical trials. These amounts can be small, just covering a partial salary for research assistants and the cost of any supplies (usually the case with national health agency studies), or be substantial and include "overhead" that allows the investigator to pay the research staff during times between clinical trials.
Sources: en.wikipedia.org
There are various competing calculation methods for the drug accumulation ratio, yielding somewhat different results. A commonly used formula defines Rac as the ratio of the area under the curve (AUC) during a single dosing interval under steady state conditions to the AUC during a dosing interval after one single dose:
==== Reserve group antibiotics ==== This group includes antibiotics and antibiotic classes that should be reserved for treatment of confirmed or suspected infections due to multi-drug-resistant organisms. Complementary:
=== Hydrodynamic chromatography === Hydrodynamic chromatography (HDC) is derived from the observed phenomenon that large droplets move faster than small ones. In a column, this happens because the center of mass of larger droplets is prevented from being as close to the sides of the column as smaller droplets because of their larger overall size. Larger droplets will elute first from the middle of the column while smaller droplets stick to the sides of the column and elute last. This form of chromatography is useful for separating analytes by molar mass (or molecular mass), size, shape, and structure when used in conjunction with light scattering detectors, viscometers, and refractometers. The two main types of HDC are open tube and packed column. Open tube offers rapid separation times for small particles, whereas packed column HDC can increase resolution and is better suited for particles with an average molecular mass larger than
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.